West Nile Virus

Contact Hours: 2

Author(s):

Author: R.E. Hengsterman MSN, RN 

Course Overview

This course comprehensively reviews West Nile Virus (WNV), a mosquito-borne zoonotic flavivirus responsible for various illnesses, from mild febrile symptoms to severe neuroinvasive diseases. Participants will explore the biology, pathophysiology, epidemiology, clinical presentations, and modes of transmission of WNV, with a focus on public health implications and preventive measures. The course emphasizes early diagnosis, supportive management, and the roles of healthcare professionals in controlling outbreaks. Learners will also examine the influence of environmental and behavioral factors, global trends in WNV spread, and the challenges posed by the absence of specific antiviral treatments and vaccines. 

Course Outline

  1. Introduction
  2. Transmission of West Nile Virus (WNV)
  3. West Nile Virus (WNV) Life Cycle
  4. Dynamics of Transmission within the Mosquito Host
  5. Infection of Vertebrate Hosts
  6. Viral Replication and Release
  7. Amplification in Crocodilians
  8. Behavioral and Immune Considerations
  9. Epidemiology
  10. Clinical Presentation in Humans
  11. Clinical Presentation in Animals
  12. Case Study: West Nile Virus (WNV) Neuroinvasive Disease
  13. Factors Influencing Susceptibility to West Nile Virus
  14. Transmission and Outbreak Trends
  15. Pathophysiology
  16. Etiology
  17. History & Physical
  18. Epidemiology and Typical Course of Illness
  19. Laboratory Findings and Diagnosis
  20. Imaging Studies
  21. Differential Diagnosis
  22. Clinical Examination
  23. Laboratory-Based Diagnostics
  24. Treatment
  25. Persistence of WNV Infection
  26. Immunity and Reinfection
  27. Coinfections with Other Pathogens
  28. Vector and Host Interactions
  29. Public Health Implications
  30. Conclusion

Course Outcomes

After completing this course, the learner will rate a 4 out of 5 on the Likert Scale for their ability to:

  1. Explain the biology, transmission cycle, and life cycle of West Nile Virus (WNV), including the roles of mosquito vectors and reservoir hosts.
  2. Identify the clinical manifestations of WNV infection in humans and animals, ranging from asymptomatic cases to severe neuroinvasive disease.
  3. Explore the epidemiology of WNV, including global trends, environmental influences, and the impact of climate change and globalization.
  4. Evaluate diagnostic methods, management strategies, and public health interventions for WNV, focusing on the interprofessional care approach.
  5. Discuss the challenges and implications of WNV persistence, immunity, coinfections, and the lack of specific antiviral treatments or vaccines.

Accreditations and Approvals

CE Credit Logo
  • American Nurses Credentialing Center (ANCC) (P0614)
  • California Board of Registered Nursing (CEP 17418)
  • Kentucky Board of Nursing (7-0090)
  • Louisiana State Board of Nursing (58)
  • Florida Board of Nursing (50-23983)
  • Delaware Board of Nursing (DE-24-010127)
  • Alabama Board of Nursing (#ABNP1577)
  • Iowa Board of Nursing (#393)
  • Kansas Board of Nursing (LT0340-0325)

Approved by the Board of Nursing in every state, you can complete your RN, LVN, and APRN CEUs with confidence.

Accreditation Statement

Nursing CE Central LLC is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

It will take the average learner 120 minutes to complete and awards 2 contact hours of continuing education.

Written For

  • Registered Nurses (RN)
  • Advanced Practice Registered Nurses (APRN)
  • Licensed Practical Nurses (LPN/LVN)

Requirements for Completion

  1. Enrollment in the course by the learner
  2. Read and learn all course materials
  3. Complete the course evaluation
  4. Attest and testify learning of the course materials

Disclosure of Relevant Financial Relationships

Nursing CE Central nor any of the authors, planners, content experts, or any contributors have any relevant financial relationships with ineligible companies to disclose.